Ritu Baral
Stock Analyst at TD Cowen
(0.80)
# 2,908
Out of 4,479 analysts
26
Total ratings
27.27%
Success rate
-20.17%
Average return
Main Sectors:
Top Industries:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $260 → $282 | $243.32 | +15.90% | 2 | Jun 25, 2024 | |
| INSM Insmed | Maintains: Buy | $45 → $67 | $66.34 | +0.99% | 2 | May 29, 2024 | |
| SAGE Sage Therapeutics | Maintains: Buy | $30 → $16 | $11.03 | +45.06% | 4 | Apr 18, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $279.31 | +39.63% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $3.16 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $156.75 | +11.64% | 1 | Mar 22, 2023 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $32 → $21 | $16.04 | +30.92% | 1 | Aug 8, 2022 | |
| SPRO Spero Therapeutics | Downgrades: Market Perform | n/a | $1.28 | - | 2 | May 4, 2022 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | n/a | $2.13 | - | 1 | Apr 19, 2022 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | n/a | $0.53 | - | 1 | Nov 23, 2021 | |
| RLYB Rallybio | Initiates: Outperform | n/a | $1.36 | - | 1 | Aug 23, 2021 | |
| GHRS GH Research | Initiates: Outperform | n/a | $11.75 | - | 1 | Jul 20, 2021 | |
| ATAI Atai Life Sciences | Initiates: Outperform | n/a | $1.35 | - | 2 | Jul 13, 2021 | |
| VERA Vera Therapeutics | Initiates: Outperform | n/a | $36.29 | - | 1 | Jun 8, 2021 | |
| TERN Terns Pharmaceuticals | Initiates: Outperform | n/a | $6.85 | - | 1 | Mar 2, 2021 | |
| PLRX Pliant Therapeutics | Initiates: Outperform | n/a | $10.86 | - | 1 | Jun 29, 2020 | |
| ASNS Actelis Networks | Downgrades: Market Perform | n/a | $2.02 | - | 2 | Jul 2, 2018 | |
| AXON Axon Enterprise | Downgrades: Market Perform | n/a | $289.21 | - | 1 | Jan 12, 2018 |
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $260 → $282
Current: $243.32
Upside: +15.90%
Insmed
May 29, 2024
Maintains: Buy
Price Target: $45 → $67
Current: $66.34
Upside: +0.99%
Sage Therapeutics
Apr 18, 2024
Maintains: Buy
Price Target: $30 → $16
Current: $11.03
Upside: +45.06%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $279.31
Upside: +39.63%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.16
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $156.75
Upside: +11.64%
ACADIA Pharmaceuticals
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $16.04
Upside: +30.92%
Spero Therapeutics
May 4, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.28
Upside: -
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.13
Upside: -
Spruce Biosciences
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.53
Upside: -
Rallybio
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.36
Upside: -
GH Research
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.75
Upside: -
Atai Life Sciences
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.35
Upside: -
Vera Therapeutics
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $36.29
Upside: -
Terns Pharmaceuticals
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.85
Upside: -
Pliant Therapeutics
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $10.86
Upside: -
Actelis Networks
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $2.02
Upside: -
Axon Enterprise
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $289.21
Upside: -